An important improvement supporting the use in the clinic of mAbs recognizing NK cell-“specific” ICs has been obtained by Andrè and collaborators who analyzed the potential of an NKG2A blocking mAb (used either alone or combined other therapeutic mAbs) to unleash NK cell effector functions against HLA-E+ tumor cells [50]. The gene discussed is KLRC1; the disease is neoplasm.